Q1 Earnings Estimate for ORMP Issued By Zacks Small Cap

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - Analysts at Zacks Small Cap issued their Q1 2025 earnings per share estimates for Oramed Pharmaceuticals in a research report issued on Thursday, April 3rd. Zacks Small Cap analyst M. Marin forecasts that the biotechnology company will post earnings per share of ($0.01) for the quarter. The consensus estimate for Oramed Pharmaceuticals' current full-year earnings is ($0.03) per share. Zacks Small Cap also issued estimates for Oramed Pharmaceuticals' Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.07) EPS.

Separately, StockNews.com lowered shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, February 19th.

Oramed Pharmaceuticals Trading Down 0.9 %

Shares of ORMP traded down $0.02 during trading hours on Monday, reaching $2.11. 94,343 shares of the stock traded hands, compared to its average volume of 157,055. Oramed Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $3.09. The company has a market cap of $86.19 million, a price-to-earnings ratio of 19.18 and a beta of 1.50. The stock has a fifty day simple moving average of $2.26 and a 200 day simple moving average of $2.33.

Remove Ads

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.04.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Peapod Lane Capital LLC purchased a new stake in shares of Oramed Pharmaceuticals during the 4th quarter valued at $550,000. BML Capital Management LLC grew its position in Oramed Pharmaceuticals by 20.9% during the fourth quarter. BML Capital Management LLC now owns 2,643,907 shares of the biotechnology company's stock valued at $6,398,000 after buying an additional 457,716 shares during the period. XTX Topco Ltd increased its holdings in Oramed Pharmaceuticals by 59.7% during the third quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company's stock worth $60,000 after buying an additional 9,242 shares during the last quarter. Marquette Asset Management LLC bought a new stake in Oramed Pharmaceuticals in the fourth quarter worth about $81,000. Finally, World Equity Group Inc. purchased a new position in Oramed Pharmaceuticals in the fourth quarter valued at about $48,000. Hedge funds and other institutional investors own 12.73% of the company's stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.